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Abstract
Stimuli-responsive drug delivery vehicles have garnered immense interest in recent years due to 
unparalleled progress made in material science and nanomedicine. However, the development of 
stimuli-responsive devices with integrated real-time monitoring capabilities is still in its nascent 
stage because of the limitations of imaging modalities. In this paper, we describe the development 
of a polypeptide-wrapped mesoporous-silica-coated multicolor upconversion nanoparticle 
(UCNP@MSN) as an adenosine triphosphate (ATP)-responsive drug delivery system (DDS) for 
long-term tracking and real-time monitoring of drug release. Our UCNP@MSN with multiple 
emission peaks in UV-NIR wavelength range was functionalized with zinc-dipicolylamine 
analogue (TDPA-Zn2+) on its exterior surface and loaded with small-molecule drugs like 
chemotherapeutics in interior mesopores. The drugs remained entrapped within the UCNP-MSNs 
when the nanoparticles were wrapped with a compact branched polypeptide, poly(Asp-Lys)-b-
Asp, because of multivalent interactions between Asp moieties present in the polypeptide and the 
TDPA-Zn2+ complex present on the surface of UCNP-MSNs. This led to luminescence resonance 
energy transfer (LRET) from the UCNPs to the entrapped drugs, which typically have absorption 
in UV–visible range, ultimately resulting in quenching of UCNP emission in UV–visible range 
while retaining their strong NIR emission. Addition of ATP led to a competitive displacement of 
the surface bound polypeptide by ATP due to its higher affinity to TDPA-Zn2+, which led to the 
release of the entrapped drugs and subsequent elimination of LRET. Monitoring of such ATP-
triggered ratiometric changes in LRET allowed us to monitor the release of the entrapped drugs in 
real-time. Given these results, we envision that our proposed UCNP@MSN-polypeptide hybrid 
nanoparticle has great potential for stimuli-responsive drug delivery as well as for monitoring 
biochemical changes taking place in live cancer and stem cells.
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Spurred by the recent advances made in material science and nanomedicine, “smart” stimuli-
responsive drug delivery systems (DDSs) are quickly emerging as a platform of choice for 
diverse bioapplications including drug delivery and biosensing. By combining the unique 
properties of advanced nanomaterials with the ability to recognize and adapt in response to a 
change in their environment, these stimuli-responsive vehicles, which deliver a therapeutic 
cargo in a spatially, temporally and dosage-controlled manner, improve the bio-
pharmaceutical properties of the delivered drugs, reduce their side effects and thereby 
enhance their clinical utility.1–5 However, the success of such stimuli-responsive DDS 
hinges upon three crucial factors: (i) the ability to construct a biocompatible nanocarrier that 
can retain high loading amounts of the therapeutic molecules, (ii) the development and 
incorporation of a stimuli-responsive molecular valve into the DDS, which will prevent the 
premature release of the drug prior to reaching the target location, and (iii) a tracking 
modality that can allow for real-time monitoring of drug release over extended periods of 
time. While several bio-compatible and/or biodegradable nanocarriers, such as polymers and 
liposomes,6–10 have been explored as DDSs over the past decade, mesoporous-silica 
nanoparticles (MSNs) have become a powerful delivery vehicle of choice, because of their 
unique structural features that enable high drug loading and versatility of functionalization.
11–14
 Additionally, a variety of endogenous (e.g., pH, enzymes and other biomolecules)15–18 
and exogenous (e.g., light, magnetic field, and temperature)19–22 stimuli have been explored 
to construct stimuli-responsive mesoporous DDSs.
Among these, biomolecule-responsive DDSs that bank upon exploiting the physiological 
and biochemical differences between normal and pathological conditions (e.g., 
microenvironment in tumors and inflammation sites) have drawn increasing attention owing 
to their swift and specific triggered drug release.23–28 One such specific biomolecular 
stimulus is adenosine triphosphate (ATP), which in addition to being the “molecular unit of 
currency” for intracellular energy transfer, is also found to be upregulated in cancerous 
tissues and neurons.29–31 There is growing evidence that the increased levels of ATP are 
implicated in many key physiological and pathological processes, such as chemoresistance, 
uncontrolled tumor growth and synaptic transmission in neurons, thereby making it an 
interesting target for exploiting the differences between normal and cancer cells, and 
studying the neuronal system.32–34
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Another critical component of the stimuli-responsive DDSs is the development of an 
integrated tracking method having the capability of imaging and monitoring not only the 
targeted tissues but also the drug release kinetics in a real-time and long-term fashion.35,36 
Such long-term tracking modalities require a highly biocompatible manner, such as 
noninvasive Raman imaging,37,38 magnetic resonance imaging,39–43 and fluorescence 
microscopy.17,44–47 Lanthanide-doped up-conversion nanoparticles (UCNPs) have gained 
tremendous attention in the field of theranostics, molecular imaging and nanomedicine, due 
to their unique ability of upconverting low-energy near-infrared (NIR) light to high-energy 
ultraviolet (UV), visible (vis) and NIR light.5,48–52 The distinctive NIR excitation that 
enables high penetration depth and low photocytotoxicity (vs UV–vis light), as well as other 
photophysical properties including narrow emission peaks and high photostability, makes 
UCNPs a promising candidate for developing DDSs with long-term tracking and real-time 
monitoring capabilities. However, to our knowledge, there have been only a few reports that 
have demonstrated UCNP-based DDSs showing such capabilities.40,41
We herein report the development of a UCNP-based DDS for long-term tracking and real-
time monitoring of drug delivery in the response to ATP. As illustrated in Scheme 1, our 
unique core–shell UCNP@MSN DDS consists of two key components: (i) a UCNP core 
with distinct emission peaks present in UV to NIR region, when excited at 980 nm, and (ii) a 
mesoporous silica shell-based “biogate” system for stimuli-responsive (e.g., ATP-
responsive) drug release. The biogate for ATP-responsive drug release comprises of a zinc-
dipicolylamine analogue (TDPA-Zn2+) immobilized on the exterior surface of the 
nanoparticle to serve as binding sites for the capping ligands, branched poly-peptides 
[poly(Asp-Lys)-b-Asp] with multiple pendant carboxylate side chains. The high binding 
affinity of the oligo-aspartate moieties in polypeptide side chains to TDPA-Zn2+ moieties on 
the surface of the UCNP@MSN allows the loaded drugs to remain entrapped inside the 
mesopores.53–55 It is expected that, because of the overlap of broad absorption peaks of 
loaded model drugs [e.g., doxorubicin (DOX) and camptothecin (CPT)] with the multiple 
sharp emission peaks of UCNP, as well as their close proximity, luminescence resonance 
energy transfer (LRET) would occur from UCNP (donor) to drug moieties (acceptor), which 
will result in quenching of the UV–vis emission of UCNPs.56–58 On the other hand, the NIR 
emission from our UCNPs will remain constant and can be utilized as a tracking signal. 
When the stimulus (e.g., ATP in our case) is present, it can lead to a competitive 
displacement of the surface bound polypeptide by ATP molecule, due to its higher binding 
affinity to TDPA-Zn2+ as compared to the oligo-aspartate in the polypeptide.59,60 As a 
result, drugs encapsulated within the mesopores can be released and the LRET signal 
between the drugs and UCNPs is diminished, which in turn enhances the UV–vis emission 
of UCNPs. Since the drug release from the mesopores of the UCNPs is accompanied by a 
simultaneous change in the LRET signal, we can monitor the real-time release of the 
entrapped drugs over an extended period of time via a ratiometric signal using the NIR 
emission of our UCNPs as an internal reference. Given the importance of ATP in tumor and 
neural microenvironment, developing such ATP-responsive multifunctional DDS can open 
new opportunities for cancer therapy and neuroscience.
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RESULTS AND DISCUSSION
Synthesis and Characterizations of TDPA-Zn2+-UCNP@MSNs
For the construction of the proposed UCNP@MSN-based DDS, we first synthesized a 
metallic complex-functionalized UCNP coated with mesoporous silica, TDPA-Zn2+-
UCNP@MSN, as shown in Figure 1A. The multicolor UCNP possesses a core–shell 
structure with a composition of β-NaYF4:Yb3+/Tm3+@NaYF4:Yb3+/Er3+.61 Such a core–
shell structure of UCNP minimizes the cross relaxation of activators, endowing the UCNP 
with bright emissions shown in UV to NIR region (360, 475, 542 and 656 nm) when excited 
with a 980 nm NIR laser (Figure 1G). The simultaneous multiplex emission of UCNP in the 
UV to NIR range is important for the multifunctionality of UCNP@MSN based DDS for 
two reasons: (1) the individual sharp emission peaks in UV–vis region can serve as an 
energy donor for LRET to entrapped drugs, such as chemotherapeutics (which typically 
absorb in the UV–vis range), thereby allowing for real-time monitoring of different drugs; 
and (2) the NIR emission, on the other hand, remains constant irrespective of the drug 
molecule present and hence can be used for imaging of the nanoparticle and quantifying the 
drug release via a ratiometric signal (Scheme 1).
Transmission electron microscopic (TEM) analysis revealed that our core–shell UCNP was 
in the hexagonal phase with a size of 21.5 ± 1.4 nm and 29.2 ± 1.2 nm (n = 100) for the core 
and shell, respectively (Figure 1B,C). The size of the particle increased to 54.3 ± 3.1 nm (n = 
100) after coating with a mesoporous silica shell (Figure 1D,E, and Supporting Information, 
Figure S2). A tyrosine modified dipicolyl derivative TDPA was successfully grafted to the 
nanoparticle surface and used as a versatile precursor for chelating different metallic ions 
such as Zn2+ and Cu2+ to produce a metallic complex,62 which further served as binding 
sites for oligo-aspartate and ATP (Figure S1). The successful grafting of binuclear metallic 
complex was confirmed using FTIR spectroscopy (Figure S3), UV–vis absorption 
spectroscopy (Figure 1F) and thermogravimetric analysis (Figure S4). Compared to the 
UCNP@MSNs, the ligand-functionalized nanoparticles showed the characteristic absorption 
peaks of TDPA at 280 and 294 nm, which underwent a red shift after chelating with Zn2+. 
This spectral change for surface-immobilized TDPA is similar to that of free TDPA in 
aqueous solution (Figure 1F inset), demonstrating the successful formation of metallic 
complex on nanoparticle surface. Additionally, the TDPA-Zn2+-UCNP@MSNs were well-
dispersed in water and retained its characteristic multicolor emissions of UCNP in the range 
from UV to NIR under 980 nm excitation (Figure 1G), thus indicating feasibility of using 
these UCNPs for the construction of our proposed multi-functional DDS.
Synthesis and Characterization of Polypeptide, Poly(Asp-Lys)-b-Asp
The multivalent coordination between the oligo-aspartate moieties on the polypeptide 
capping ligands and the zinc-dipicolylamine analogues (Dpa-Zn2+) offer a strong binding 
affinity with a binding constant of 6.9 × 105 M−1 when the peptide consists of four or more 
aspartate moieties.53–55 To develop the ATP-responsive molecular valve in our DDS, we 
synthesized a compact block polypeptide containing oligo-aspartate side chains using N-
carboxyl anhydride (NCA) based ring opening metathesis polymerization (ROMP) 
technique with two-generation polymerization.63–65 This technique allows for extensive 
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control over the polymerization process, thereby leading to the production of highly 
monodisperse synthetic polypeptides, while avoiding any unfavorable side reactions. As 
shown in Figure S5, by varying the molar ratio of the two monomers (x:y), Asp(OBzl)-NCA 
and Lys(Cbz)-NCA during the synthesis of tribranched co-polypeptide backbone (first-
generation polymerization, G1), we were able to incorporate different amounts of Lys on the 
polymer backbone, which subsequently served as an initiator for the second-generation 
polymerization. Further polymerization with Asp(OBzl)-NCA led to generation of block 
polypeptides with varying degrees of compactness. The as-synthesized polypeptides were 
characterized by MALDI-TOF mass spectrum (Figure S6), 1H NMR spectrum (Figure S15–
S20), and fluorescamine-based fluorescence analysis (see Supporting Information for more 
details), for confirming their composition and mean molecular weight. The abundant 
terminal NH2 groups of the branched structure allow for facile functionalization of 
polypeptide, such as labeling with fluorescent dyes and targeting molecules. Using the 
above-mentioned procedure, we have synthesized four different polypeptides (G2di, i = 1, 2, 
3 and 4) with various ratios of the three components (x, y, and z) as shown in Scheme 2 and 
Table 1. The amount of Lys present increased from polypeptide G2d1 and G2d2 to 
polypeptide G2d3 and G2d4, which indicated an increased number of side chains. 
Furthermore, the polypeptide G2d2 and G2d4 were designed to have longer branches 
consisting of eight Asp while the other two peptides, G2d1 and G2d3 consisted of only four 
Asp. Such changes in the length of the side chains could modulate the structural 
compactness of the polypeptide and control the binding affinity of the polypeptide to the 
metallic complex, and as a result influence the selectivity and responsiveness of the DDS to 
nucleoside-polyphosphates (ATP).
ATP-Responsive Drug Release
The synthetic block polypeptides were expected to bind to the surface of TDPA-Zn2+-
UCNP@MSN, because of the multivalent interactions between the oligo-aspartate side 
chains and the TDPA-Zn2+ motifs, with a binding constant as large as 6.9 × 105 M−1.54 To 
verify this, we performed the DLS size and ζ-potential characterizations of the UCNPs 
wrapped with different block polypeptides in aqueous solutions. As shown in Table S1, the 
hydrodynamic size of TDPA-Zn2+-UCNP@MSN is 65 ± 4 nm with a ζ-potential of +22.5 
mV. However, coating with poly-peptide G2d2 and G2d4 increased the hydrodynamic size to 
87 ± 6 nm and 91 ± 7 nm respectively, because of the hydration of polypeptides in aqueous 
solutions. In addition, the G2d2 and G2d4-wrapped nanoparticles were highly negatively 
charged with a ζ-potential at −25.4 and −32.1 mV, respectively, which could be attributed to 
the abundant carboxylate side chains of these polypeptides. Taken together, these results 
demonstrated the successful binding of polypeptides to UCNP surface. After binding to the 
UCNP surface, the compact multibranched structure of the poly-peptide was expected to 
entrap the drug molecules inside the pores of nanoparticles effectively. The addition of ATP 
would then cause competitive displacement of the polypeptides from the UCNP due to 
higher binding affinity of ATP to the TDPA-Zn2+(4.0 × 107 M−1)59,60 as compared to oligo-
aspartate (6.9 × 105 M−1)53–55 and eventually trigger the release of the entrapped drugs.
To test this hypothesis, we used fluorescein as a model drug and prepared block polypeptide 
(G2d1–G2d4)-wrapped fluorescein-loaded TDPA-Zn2+-UCNP@MSNs as explained earlier. 
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The amount of dye loaded was calculated to be 13.2 mg fluorescein/g of UCNP@MSN. 
Thereafter, we showed that the G2d2-wrapped dye-loaded nanoparticles suspended in 
HEPES buffer solution (pH 7.4, 10 mM) were stable and negligible leakage of fluorescein 
was observed in the absence of ATP (Figure 2A, curve a), indicating the drug (fluorescein) 
was entrapped efficiently within the mesopores by the compact block polypeptide. In 
contrast, the addition of 1 mM ATP led to a rapid release of the fluorescein from the 
nanoparticles (curve b), with increasing amounts of fluorescein released upon addition of 
increasing amounts of ATP (curve c, d). These results revealed an ATP-responsive and ATP 
concentration-dependent drug release property of our UCNPs. Furthermore, we monitored 
ATP-triggered fluorescein release from TRITC-labeled G2d2-wrapped UCNPs. Comparison 
of the release profiles of both the TRITC-polypeptide and fluorescein dye clearly showed 
that the uncapping of polypeptide from UCNP surface occurs prior to fluorescein release 
from the pores, as can be seen from the rapid increase in TRITC emission (Figure S7). This 
result demonstrated the release of encapsulated dye was indeed due to the uncapping of the 
polypeptide as a result of the competitive binding of ATP to the TDPA-Zn2+ complex.
It is worth noting that the ATP-responsive drug release profiles of the UCNPs can also be 
controlled by using different polypeptides shown in Table 1. As shown in Figure 2B, in the 
presence of the same ATP concentration, UCNPs wrapped by polypeptide with more side 
chains (G2d3 and G2d4) showed slower and less dye release (curve c and d), as compared to 
that of polypeptides with less side chains (G2d1 and G2d2, curve a and b). This can be 
attributed to the increasing number of Asp side chains, which result in higher binding 
affinity of polypeptides to TDPA-Zn2+ on UCNP surface. A similar pattern of drug release 
was observed in case of polypeptides with longer side chains (G2d4). It showed that G2d4-
wrapped UCNP@ MSN has the lowest amount of dye release as well as the slowest release 
kinetics (curve d) as compared to other polypeptide wrapped nanoparticles, again suggesting 
that increasing number of Asp moieties can lead to more strongly bound polypeptide and 
hence slower drug release. Apart from using different polypeptides, the release kinetics 
could also be modulated by using nanoparticles with different metallic ion complexes. 
Figure S8 showed the ATP concentrations-dependent drug release profiles of G2d2-wrapped 
UCNP@MSNs functionalized with TDPA-Zn2+ and TDPA-Cu2+. The Cu2+-complex 
functionalized nano-particle was found to be around 10-fold more sensitive to ATP upon 
drug release than that of Zn2+ complex nanoparticle. Addition of 50 μM ATP to the 
fluorescein loaded TDPA-Cu2+-UCNP@MSNs induced a remarkable dye release (18%), 
while 100% dye release was achieved in the presence of 1 mM ATP. This is due to the 
relatively weak binding affinity between TDPA-Cu2+ complex and the polypeptide (Kapp < 
103 M−1) as compared to that between TDPA-Zn2+complex and polypeptide (Kapp = 4.0 × 
107 M−1).62 These results demonstrate that we can develop a wide variety of ATP-sensitive 
DDS, where both the metallic complex and the polypeptide can be used to modulate the 
drug release kinetics in response to ATP.
We further evaluated the specificity of stimulus-responsive uncapping action of our DDS. 
For this purpose, various phosphate-containing biomolecules including the nucleoside 
phosphates (ADP, AMP, GTP, UTP, and nucleic acids), proteins (e.g., bovine serum 
albumin), enzymes (e.g., glutathione) and inorganic phosphates were used to trigger the 
release of fluorescein from the G2d2-wrapped nanoparticles. As expected, the ATP 
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analogues (GTP, UTP, CTP) as well as pyrophosphate (PPi) showed comparable release of 
fluorescein as observed for ATP, whereas the mono-and biphosphate analogues (AMP and 
ADP) showed lower drug release (Figure 2C). However, biomolecules like GSH, DNA and 
BSA commonly found in the cytoplasm showed negligible release of fluorescein, while the 
trypsin, a typical protease for proteolysis, only induced a 18.3% of release in 24 h, thus 
indicating the release of the cargo via uncapping of the polypeptide is in a “triphosphate-
specific” fashion. Additionally, the effect of different pH conditions on the ATP-responsive 
release was also tested. As shown in Figure 2D, negligible release of fluorescein was 
observed when the polypeptide wrapped nanoparticles were dispersed in solutions of 
different pH conditions ranging from 5 to 9 in the absence of ATP, thus demonstrating the 
robustness of the polypeptide-TDPA-Zn2+ complex. However, addition of 5 mM ATP led to 
a remarkable release of fluorescein at all pH conditions, indicating the pH-independence of 
the ATP-responsive drug release. Overall, these results demonstrated the successful 
construction of the proposed polypep-tide-wrapped TDPA-Zn2+-UCNP@MSNs based DDS 
that possesses ATP-specific stimuli-responsive drug release properties.
Correlating Drug Release from Hybrid Nanoparticle to the Ratiometric Emission Signal of 
UCNP
After confirming the ATP-specific triggered release properties of the poly-peptide-wrapped 
TDPA-Zn2+-UCNP@MSNs, we then studied real-time monitoring of drug release using our 
system. Our UCNPs were rationally designed to have multiple emission peaks in UV to NIR 
range (Figure 1G). We hypothesized that when anticancer drug (DOX or CPT) was loaded 
into pores of the UCNP@MSNs (Figure 3A), a LRET between the loaded drugs and UCNP 
will occur resulting in quenched UV–vis emission of UCNP. However, the NIR emission 
will remain constant in this scenario (the absorption of the drug typically is in the UV–vis 
region), thus allowing for long-term tracking and imaging of the drug delivery. Upon ATP-
triggered drug release, we expected to observe an enhancement on the UV–vis emission of 
UCNP due to the elimination of the LRET. As a result, the drug release can be monitored in 
real-time by monitoring the changes in LRET via a ratiometric signal by utilizing the NIR 
emission of the UCNP as an internal reference.
To verify this hypothesis, G2d2-wrapped nanoparticles loaded with anticancer drugs DOX or 
CPT were prepared. DOX and CPT have an absorption maximum at 480 and 370 nm, 
respectively (Figure 3B), which overlaps well with the blue (475 nm) and UV (365 nm) 
emission of UCNP. As expected, loading with DOX induced a significant quenching of the 
blue emission while only slightly quenching the UV and green emissions of UCNP (Figure 
3C). In contrast, loading with CPT only quenched the UV emission of UCNP (Figure 3D). 
The absorption wavelength-dependent emission quenching of UCNP strongly indicated the 
LRET within the drug loaded nanoparticle. This was further supported by observing a 
shortening in the Tm decay at 451 nm with DOX loading, which demonstrated a dynamic 
quenching of the Tm emission (Figure S9). In addition to LRET, both DOX and CPT loaded 
nanoparticles retained the ATP-responsive drug release property. Addition of 1 mM ATP to 
the drug loaded nanoparticles induced a time dependent release of the encapsulated drug 
(Figure 3C,D), which was accompanied by a simultaneous luminescence enhancement of 
UCNP emission. As seen in Figure 3E, there is a linear correlation between the ratiometric 
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signals of the UCNP emission to the amount of the drug release. On the basis of these 
results, the time-dependent release profile for DOX and CPT can be established by 
measurement of the emission of UCNP, thus strongly demonstrating the capability of the 
proposed DDS for real-time monitoring of drug release kinetics.
Real-Time Monitoring of DOX Release Using Polypeptide Wrapped TDPA-Zn2+-
UCNP@MSNs in Cancer Cells
Prior to testing our ATP-responsive DDS in vitro, we first evaluated their biocompatibility in 
cervical cancer cells (HeLa). Our polypeptide wrapped TDPA-Zn2+-UCNP@ MSNs 
exhibited negligible cytotoxicity in HeLa cells over a wide range of concentrations tested 
(see Supporting Information, Figure S10). After establishing that our UCNP@MSN-based 
DDS was indeed biocompatible, we then demonstrated targeted delivery of our 
UCNP@MSN by using a folic acid (FA) labeled polypeptide.66 As shown in Figure S11, 
UCNPs wrapped with FA modified polypeptides can be selectively uptaken by HeLa cells 
which have been shown to overexpress folate receptors (FRs). In contrast, MCF-7 cells, 
which lack FR, showed minimal uptake of the nanoparticle. UCNPs without FA ligands 
were not uptaken by HeLa cells while uptaken in negligible amounts by MCF-7 cells. The 
differential uptake of our FA-modified UCNPs in HeLa and MCF-7 cells demonstrated the 
target-specific delivery ability of our UCNP@MSN based DDS.
We further examined its capability in real-time monitoring of the intracellular drug release 
by incubating the HeLa cells with our UCNPs and monitored their ratiometric upconversion 
luminescence signals at different time points after incubation. It shown that after 3 h of 
incubation (Figure 4A–E), the UCNPs showed punctate red emission (656 nm) with 
negligible blue emissions (475 nm) as well as weak emission for DOX (590 nm), indicating 
that most of the DDS were entrapped in endosomes at 3 h post incubation and limited 
amount of DOX was released. This nanoparticle-endosome colocalization was further 
confirmed by cross-sectional TEM of HeLa cells as shown in Figure S12. However, as time 
progressed, a time-dependent enhancement of fluorescence intensity (590 nm) coupled with 
diffuse dispersion of DOX within the cancer cells was obtained, thus demonstrating the 
ATP-triggered release of DOX from the DDS (Figure 4I,N). Meanwhile, an intracellular 
diffusion and recovery of UCL signal at 475 nm DDS is clearly detectable, as shown in 
Figure 4C, H,M. Because of the absence of overlap of DOX absorption with UCL emission 
at the 656 nm, there is negligible variation in emission intensity within different time points 
(Figure 4B,G,L), which further confirmed the quantification capability of this DDS using the 
656 nm emission as an internal reference, as shown in Figure 3E. The merged images 
(Figure 4E,J,O) clearly revealed a color change of the cell from red to blue color along the 
time scale, which strongly suggested that the proposed DDS has the capability of monitoring 
the drug release in real-time.
CONCLUSIONS
In summary, we have developed an ATP-responsive upconversion nanoparticle-mesoporous 
silica (UCNP@ MSN)-based DDS with the ability of long-term tracking and real-time 
monitoring of the drug delivery in vitro. The mechanism behind ATP-response is the 
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competitive binding between multibranched polypeptides and ATP to metallic complex 
TDPA-Zn2+ immobilized on nanoparticle surface. The structural design of polypep-tide and 
metallic complex allowed for exquisite flexibility for modulating the specificity and 
sensitivity of this small molecule triggering system. Our developed DDS is biocompatible 
and can be easily functionalized to achieve additional advantages such as targeted delivery. 
Moreover, the use of UCNPs in this DDS not only offers a noninvasive approach for long-
term tracking of drug delivery by using its NIR excitation (980 nm) and emission (656 nm), 
but also provides a unique method for real-time monitoring the intra-cellular drug-release 
kinetics via a LRET mechanism combined with a ratiometric signal. The multiemission 
peaks of UCNP enable the real-time monitoring strategy to be applied to various drugs with 
different UV–vis absorption properties. Because of the wide availability of ATP in all live 
cells, especially in the neural stem cells and cancer cells, engineering such a multifunctional 
ATP-responsive DDS affords great promise for neural stem cell investigation and cancer 
therapy. It should be noted that the use of high-power 980 nm excitation for UCNP in long-
term tracking can potentially cause localized heating, which would result in detrimental 
effects on biological system. However, construction of a multicolor UCNP with 808 nm NIR 
light as excitation can enable us to overcome this limitation and further improve the 
biocompatibility of our DDS.
METHODS
Synthesis of Core–Shell UCNP61
(a). Synthesis of β-NaYF4: 30 mol % Yb3+, 0.5 mol % Tm3+ Nanoparticles (β-
NaYF4:Yb3+/Tm3+)—Y(CH3CO2)3 · xH2O (1.39 mmol), Yb(CH3CO2)3 · xH2O (0.6 
mmol), and Tm(CH3CO2)3 · xH2O (0.01 mmol) were added to a 100 mL flask containing 12 
mL of oleic acid and 15 mL of 1-octadecene. The mixture was heated at 130 °C for 30 min 
under a vacuum to form the lanthanide-oleate complexes and remove water. Then the 
solution was cooled to 50 °C naturally under argon. Thereafter, 12 mL of methanol solution 
containing NH4F (8 mmol) and NaOH (5 mmol) was added, and the resultant solution was 
stirred for 30 min. After the methanol was evaporated, the solution was heated to 300 °C 
(15 °C · min−1) under argon for 90 min and then cooled to RT. The resulting nanoparticles 
were precipitated by addition of ethanol (30 mL), collected by centrifugation at 1500g for 5 
min, washed with ethanol several times, and redispersed in 10 mL of hexane.
(b). Synthesis of β-NaYF4: 30 mol % Yb3+, 0.5 mol % Tm3+@β-NaYF4: 18 mol % 
Yb3+, 2 mol % Er3+ Core–Shell Nanoparticles (β-NaYF4:Yb3+/Tm3+@β-
NaYF4:Yb3+/Er3+)—Y(CH3CO2)3 · xH2O (1.28 mmol), Yb(CH3CO2)3 · xH2O (0.288 
mmol)), and Er(CH3CO2-)3 · xH2O (0.032 mmol) were added to a 100 mL flask containing 
12 mL of oleic acid and 15 mL of 1-octadecene. The mixture was heated at 130 °C for 30 
min under a vacuum to form the lanthanide-oleate complexes and remove water. Then the 
solution was lowered to 80 °C under argon, and the dispersion of β-NaYF4:Yb3+/Tm3+ core 
nanoparticles in hexanes obtained in last step was added. The resulting solution was heated 
at 90 °C to remove the hexane. Then the solution was cooled to 50 °C, and 10 mL of 
methanol solution containing NH4F (7.2 mmol) and NaOH (4.5 mmol) was added, and the 
resultant solution was stirred for 30 min. After the methanol was evaporated, the solution 
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was heated to 300 °C under argon for 90 min and then cooled to RT. The resulting 
nanoparticles were precipitated by addition of ethanol (20 mL), collected by centrifugation 
at 1500g for 5 min, washed with ethanol several times, and redispersed in 10 mL of hexane.
Synthesis of UCNP@MSNs
In a typical procedure, 40 mg of UCNPs in chloroform (1 mL) were poured into aqueous 
CTAB solution (10 mL, 360 mg), and the resulting solution was sonicated by using a probe-
type sonicator at 400 W for 30 min to result in a transparent UCNPs@CTAB solution. The 
nanoparticles were collected by centrifugation (13000g) and were redispersed in 1 mL of 
water. The cenctrifugation/redispersion procedure was repeated 3 times to remove the excess 
amount of CTAB. Thereafter, the UCNP@CTAB solution (1 mL) was added to a CTAB 
solution (9 mL, 8.2 mg · mL−1) and NaOH solution (0.1 mL, 0.1 M). The mixture was 
stirred at for 30 min and 50 μL of TEOS was added. The mixture was further stirred at 55 °C 
for 4 h, and the as-synthesized UCNP@MSNs were collected by centrifugation (7000g) and 
washed with water 3 times.
Synthesis of TDPA-Zn2+/Cu2+-UCNP@MSNs
(a). Boc-TDPA—Boc-TDPA was synthesized by a previously reported method.54 1H NMR 
(300 MHz, CDCl3): δ 8.53 (d, J = 4.8 Hz, 4H), 7.61 (t, J = 7.8 Hz, 4H), 7.46 (d, J = 7.8 Hz, 
4H), 7.12 (t, J = 5.7 Hz, 4H), 7.01 (s, 2H), 5.23 (d, J = 7.6 Hz, 1H), 4.51 (m, 1H), 3.86 (s, 
8H), 3.78 (s, 4H), 3.62 (s, 3H), 2.98 (s, 2H), 1.34 (s, 9H). ESI-MS m/z cal. 717.86 found 
739.9 [M + Na]+.
(b). TDPA-UCNP@MSNs—To the mixture of 70 mg of Boc-TDPA and 5 mL of CH2Cl2 
in ice bathe was added a solution of trifluoroacetic acid (TFA, 1 mL). The mixture was 
stirred at 4 °C for 30 min and then 1.5 h at RT. The mixture was concentrated in a vacuum 
and extracted by ethyl acetate. After washed with saturated NaHCO3 and NaCl solution and 
dried over anhydrous Na2SO4, the solution was concentrated to 5 mL in a vacuum. Twenty 
microliters of 3-(triethoxysiliyl)propyl isocyanate was added to the solution and refluxed 
overnight. After the solvent was removed, the mixture was added to a toluene-methanol 
solution (50 mL/3 mL) in which 200 mg of UCNP@MSNs were dispersed and refluxed for 
overnight. The nanoparticles were collected by centrifugation and washed with methanol for 
several times, and dried in a vacuum to obtain the TDPA-UCNP@MSNs.
(c). TDPA-Zn2+-UCNP@MSNs—To form the metallic Zn2+ chelated complex on TDPA-
Zn2+ on UCNP@MSNs surface, 100 mg of the TDPA-UCNP@MSNs was dispersed in 3 
mL of methanol with 1 mL of 10 mM Zn(NO3) aqueous solution and stirred for 1 h in RT. 
The nanoparticles were collected by centrifugation and washed by water for several times. 
After drying in a vacuum, the TDPA-Zn2+-UCNP@MSNs was obtained as a slight yellow 
powder.
(d). TDPA-Cu2+-UCNP@MSNs—The TDPA-Cu2+-UCNP@MSNs were prepared by 
using the same method for TDPA-Zn2+-UCNP@MSNs, while using CuCl2 as metallic 
source.
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Synthesis of Block Polypeptide Poly(Asp-Lys)-b-Asp
(a). Synthesis of β-Benzyl ester-L-aspartic acid-N-carboxyanhydride, 
Asp(OBzl)-NCA.64—The Asp(OBzl)-NCA was synthesized by a previously reported 
method. 1H NMR (400 MHz, DMSO-d6): δ 8.99 (s, 1H), 7.35–7.38 (m, 5H), 5.13 (s, 2H), 
4.69 (t, J = 4.4 Hz, 1H), 3.07 (dd, J = 4.8, 17.6 Hz, 1H), 2.90 (dd, J = 4.0, 18 Hz, 1H).
(b). Synthesis of N-ε-Benzyloxycarbonyl-L-lysine-N-carboxyan-hydride, 
Lys(Cbz)-NCA.65—The Lys(Cbz)-NCA was synthesized by a previously reported method. 
1H NMR (300 MHz, DMSO-d6): δ 9.09 (s, 1H), 7.26–7.38 (m, 5H), 5.01 (s, 2H), 4.40 (t, J = 
5.4 Hz, 1H), 2.99 (m, 2H), 1.67–1.74 (m, 2H), 1.32–1.44 (m, 4H).
(c). Synthesis of the First-Generation Tribranched Copolypeptide, G1—The 
polypeptide was synthesized by using N-carboxyanhydride (NCA) based ROMP method. 
The molar ratio of the two NCA monomers, Asp(OBzl)-NCA and Lys(Cbz)-NCA, was 
varied to synthesize different polypeptides that will lead to different amounts of branches in 
final polypeptide products (G2d). The following describes the typical procedure for 
synthesis of a G1 with a monomer ratio (Asp to Lys) at 3:1.
To a mixture of Asp(OBzl)-NCA (600 mg) and Lys(Cbz)-NCA (183 mg) in 10 mL of 
anhydrous DMF was added 7.3 mg of tris-(2-aminoethyl)amine (TAEA). The mixture 
solution was stirred at 45 °C for 72 h under Ar. The polypeptide was precipitated with 20 
mL of diethyl ether. The obtained solid was collected by centrifugation and redispersed into 
5 mL of THF, which was then added dropwise into a 20 mL of diethyl ether solution to 
precipitate the polypeptide. After this precipitation-redispersion procedure was repeated for 
3 times, the polypeptide was collected and dried under a vacuum. The ratio of Asp to Lys 
(x:y) in this polypeptide was calculated by a fluorescence analysis method, which is 
described in the below section. 1H NMR (500 MHz, DMSO-d6): δ 8.18 (CONH), 7.16–7.35 
[ArH, Asp(OBzl) + Lys (Cbz)], 5.02 [Ar–CH2, Asp(OBzl) + Lys (Cbz)], 4.64 [α–CH, 
Asp(OBzl)], 4.20 [α–CH, Lys(Cbz)], 2.96 [ε–CH2, Lys(Cbz)], 2.63–2.84 [β–CH2, 
Asp(OBzl)], 1.25–1.62 [β, γ and δ–CH2, Lys(Cbz)]. The signals for CH2 in TAEA overlap 
with DMSO-d6 and H2O and cannot be isolated.
(d). Synthesis of Polypeptide Core, Gc—Polypeptide core (Gc) was obtained through 
selective deprotection of Lys(Cbz) in polypeptide G1. Typically, to 200 mg of G1 dispersed 
in 3 mL of TFA was added 0.1 mL of 33% solution of HBr in CH3COOH. After stirring at 
RT for 1 h, 5 mL of diethyl ether was added, and the precipitation was isolated via 
centrifugation. The solid was washed with 10 mL of NaHCO3 (0.1 M) and redispersed in 3 
mL of THF, which then was added dropwise into 20 mL of diethyl ether solution to 
precipitate the polypeptide again. The Gc was collected and dried under a vacuum. 1H NMR 
(500 MHz, DMSO-d6): δ 8.18 (CONH), 7.16–7.35 [ArH, Asp(OBzl)], 5.02 [Ar–CH2, 
Asp(OBzl)], 4.64 [α–CH, Asp(OBzl)], 2.90–3.62 (β–CH2 for Asp-(OBzl) and CH2 for 
TAEA), 2.52–2.88 (ε–CH2 for Lys), 1.22–1.98 (β, γ and δ–CH2 for Lys).
(e). Synthesis of the Second-Generation Branched Polypeptide, G2—
Multibranched polypeptide G2 was synthesized using the similar synthetic method for G1 
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with Gc as macro initiator and Asp(OBzl)-NCA as monomer. 1H NMR (500 MHz, DMSO-
d6): δ 8.18 (CONH), 7.16–7.35 [ArH, Asp(OBzl)], 5.02 [Ar–CH2, Asp-(OBzl)], 4.64 [α–
CH, Asp(OBzl)], 2.90–3.62 (β–CH2 for Asp(OBzl) and CH2 for TAEA), 2.52–2.88 (ε–CH2 
for Lys), 1.22–1.78 (β, γ and δ–CH2 for Lys).
(f). Deprotection of the G2 to Achieve the Final Polypeptide, G2d—The 
polypeptide G2d was synthesized by deprotection of G2. Typically, 500 mg of G2 was 
dispersed in 5 mL mixture of methanol/water (1/1, v/v) by sonication. The solution was 
mixed with 100 mg of Pd/C (5%) and charged with H2 under vigorous stirring for 36 h. The 
mixture was filtered off to obtain a clear solution which was washed with 5 mL of ethyl 
acetate. The solvent was removed and dried under a vacuum to obtain the polypeptide G2di 
(i = 1, 2, 3 and 4). 1H NMR (500 MHz, D2O): 4.62–4.85 (α–CH for Asp, overlap with 
D2O), 4.21–4.43 (α–CH Lys), 2.76–3.05 (β–CH2 for Asp), 1.25–1.78 (β, γ, δ–CH2 for Lys).
Preparations of Drug Loaded Nanoparticles
To load drug into the TDPA-Zn2+-UCNP@MSNs, small molecular drugs such as DOX, CPT 
and model drug fluorescein were stirred together with the nanoparticles in HEPES buffer 
solution (10 mM, pH 7.4) for 2 h. Thereafter, the nanoparticles were collected by 
centrifugation (5000g) and were redispersed into a HEPES solution of polypeptide (G2di) 
with sonication. The final drug-loaded polypeptide-wrapped nanoparticles were collected by 
centrifugation (6000g) and repeat washed with water to remove the traces of free drugs and 
unbound polypeptide.
Characterizations
UV–vis absorption spectra were recorded on a Varian Cary 50 spectrophotometer. 
Fluorescence spectra were recorded on a Varian Cary Eclipse fluorescence 
spectrophotometer with an external NIR laser with a wavelength at 980 nm as excitation 
light source (CNI high power fiber coupled diode laser system, FC-W-980). The total output 
powers for the lasers are tunable from 1 mW to 10 W. The power density was detected by 
1916-R hand-held optical power meter with 818P thermophile detector (Newport 
Corporation, USA). FT-TR spectra were collected on an Avatar Nicolet FT-IR330 
spectrometer. 1H NMR and 13C NMR were acquired on Varian 300/400/500 MHz NMR 
spectrometer. ESI-MS was collected on Finnigan LCQ DUO LC/MS spectrometer. MALDI-
TOF spectrum was recorded on an ABI-MDS SCIEX 4800 MALDI-TOF/TOF mass 
spectrometer. The DLS size and zeta potential was collected on a Malvern Zetasizer nano S. 
Transmission electron microscopy (TEM) was performed on a Topcon 002B electron 
microscope at 200 kV. Sample preparation was carried out by placing a drop of the freshly 
prepared colloidal solution on a carbon-coated copper grid and allowing the solution to 
evaporate. Upconversion luminescent/fluorescence imaging of HeLa cells were performed 
on a Olympus IX83 inverted motorized microscope adapt with an additional external NIR 
laser with a wavelength at 980 nm as excitation light source (CNI high power fiber coupled 
diode laser system, FC-W-980, output power is set at 1W).
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Cell-Lines and Culture
HeLa cells and MCF-7 cells were used this project. Cells were cultured in the DMEM based 
medium supplemented with 10% FBS and 1% streptomycin–penicillin. For the delivery 
experiment, passaged cells were prepared to 40–60% confluency in 24-well plates. After 24 
h of plating, media was changed with serum-free basal media (500 μL) and polypeptide-
wrapped TDPA-Zn2+-UCNP@MSNs/PEI complexes (20 k, 20 μM, 10 μL) were added. 
After incubation for 3 h, media was exchanged with normal growth medium.
Measurement of Cytotoxicity
The viabilities of HeLa cells that incubated without or with different concentrations of 
polypeptide G2d2 wrapped TDPA-Zn2+-UCNP@MSNs were measured by quantifying the 
cellular ability to reduce the water-soluble tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) to its insoluble formazan salt. Data points were 
collected in triplicate and expressed as normalized values for control cells (100%).
Imaging of Polypeptide-Warped UCNP@MSN
At different time points following transfection, the cells were imaged using fluorescent 
microscopy. Upconversion luminescent/fluorescence imaging of cells were preferment on a 
Olympus IX83 inverted motorized microscope adapt with an external NIR laser with a 
wavelength at 980 nm as excitation light source (CNI high power fiber coupled diode laser 
system, FC-W-980, output power is set at 1W).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(A) Structural illustration of core–shell TDPA-Zn2+-UCNP@MSN. (B) TEM 
characterization of the UCNP core, β-NaYF4: Yb3+/Tm3+ and (C) after growth of a 
NaYF4:Yb3+/Er3+ shell. The inset of (B) shows the HR-TEM image of (100) 
crystallographic planes of the UCNP, confirming the hexagonal phase. (D,E) TEM 
characterization of the TDPA-Zn2+-UCNP@MSNs clearly revealed the core–shell 
nanoparticle with a mesoporous silica shell. (F) UV–vis absorption spectrum of the 
UCNP@MSNs (black line), TDPA-UCNP@MSNs (blue line) and TDPA-Zn2+-
UCNP@MSNs (red line) in HEPES buffer solution (pH 7.4, 10 mM). The appearance of the 
characteristic absorption peak of TDPA at 270 and 290 nm indicated the successful 
conjugation of TDPA to the nanoparticle surface. The successful chelating of TDPA with 
Zn2+ to form metallic complex was confirmed by obtaining a red-shift of the peak at 290 to 
312 nm, a similar spectral change observed in the formation of TDPA-Zn2+ complex (25 
μM) in HEPES solution, as shown in the inset. (G) Upconversion luminescence of the UCNP 
(1 wt % in cyclohexane) and TDPA-Zn2+-UCNP@MSN (5 wt % in HEPES buffer, pH 7.4, 
10 mM) with an excitation at 980 nm (80 W · cm−2).
Lai et al. Page 17
ACS Nano. Author manuscript; available in PMC 2018 February 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
(A) Model drug fluorescein release profile of polypeptide G2d2-wrapped TDPA-Zn2+-
UCNP@MSNs in HEPES solution in the presence of different amount of ATP: a, 0; b, 1 
mM; c, 5 mM; and d 10 mM. (B) Release of fluorescein from TDPA-Zn2+-UCNP@MSNs 
wrapped with different peptides in HEPEs solution in the presence of 5 mM ATP. a, G2d1; 
b, G2d2; c, G2d3; d, G2d4. (C) Release of fluorescein from G2d2-wrapped TDPA-Zn2+-
UCNP@MSN in response to various biomolecules, indicates the specific binding of the 
polypeptide wrapped nanoparticles for ATP and its analogues. Nanoparticle is 0.2 wt % 
dispersion in 10 mM pH 7.4 HEPES buffer solution. Various biomolecules were added to the 
nanoparticles solution and incubated for 4 h to monitor the release of fluorescein, except that 
trypsin was incubated with nanoparticles solution at 37 °C for 24 h. (D) Fluorescein release 
from G2d2-wrapped TDPA-Zn2+-UCNP@MSNs at different pHs in the absence and 
presence of 5 mM ATP. pH was adjusted using 0.1 M NaOH and 0.1 M HCl solution.
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Figure 3. 
(A) Schematic illustration of the working mechanism for the real-time monitoring of drug 
release using the proposed polypeptide-wrapped multicolor TDPA-Zn2+-UCNP@MSN. (B) 
Spectrum overlaps between the UV–vis absorption of anticancer drug DOX (30 μM in 
water) and CPT (20 M in methanol), and the emission of the core–shell UCNP@MSN (5 wt 
% in HEPES buffer). (C–D) Time dependent emission spectrum of the G2d2-wrapped 
TDPA-Zn2+-UCNP@MSNs load with DOX and CPT, respectively, in HEPES solution in the 
presence of 5 mM ATP. Concentration for nanoparticle is 0.2 wt %. The enhancement in the 
UV–vis emission indicated the progressive release of encapsulated anticancer drugs. (E) 
Linear relationships between the amount of drugs released and the ratiometric signal (R) of 
the UCNP, where the R for DOX is the ratio of I472nm to I656nm, and R for CPT is the ratio 
of I365nm to I656nm. The power density of 980 nm excitation was kept at 80 W · cm−2. (F) 
Time-dependent release profiles for DOX and CPT monitored by using the ratiometric signal 
of UCNP.
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Figure 4. 
Fluorescence microscopy images depicting the change in emission signal of UCNP and 
DOX in HeLa cells treated with polypeptide G2d2-wrapped TDPA-Zn2+-UCNP@MSNs at 
3, 8, and 24 h after incubation.
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Scheme 1. 
Schematic representation of the real-time monitoring of ATP-responsive drug release from 
polypeptide wrapped TDPA-Zn2+-UCNP@MSNs. Small molecule drugs were entrapped 
within the mesopores of the silica shell on the hybrid nanoparticle by branched polypeptide 
capping the pores through a multivalent interaction between the oligo-aspartate side chain in 
the polypeptide and the TDPA-Zn2+ complex on nanoparticles surface. The UV–vis 
emission from the multicolor UCNP under 980 nm excitation was quenched because of the 
LRET between the loaded drugs and the UCNP. Addition of small molecular nucleoside-
polyphosphates such as ATP led to a competitive binding of ATP to the TDPA-Zn2+ 
complex, which displaced the surface bound compact polypeptide because of the high 
binding affinity of ATP to the metallic complex. The drug release was accompanied with an 
enhancement in the UV–vis emission of UCNP, which allows for real-time monitoring of the 
drug release via a ratiometric signal using the NIR emission of UCNP as an internal 
reference.
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Scheme 2. 
Molecular structure of G2d, poly(Asp-Lys)-b-Asp.
Lai et al. Page 22
ACS Nano. Author manuscript; available in PMC 2018 February 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lai et al. Page 23
TABLE 1
Mean Molecular Weight and Composition of the Synthesized Polypeptides
polypeptide Mw (g/mol)a x, y, za x:yb
G2d1 6382 6, 1, 5 7:1
G2d2 10335 6, 1, 11 7:1
G2d3 8346 5, 2, 5 3:1
G2d4 12750 5, 2, 10 3:1
a
Determined by fluorescamine based fluorescence assay.
b
Determined by 1H NMR. Only the ratio x:y can be obtained. For more details, see Supporting Information.
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